Lenvatinib, Nivolumab, and Chemotherapy for Metastatic Gastric Cancer With Malignant Ascites

This clinical trial is focused on finding better treatment options for patients with advanced gastric cancer that has spread to the lining of the abdomen, causing a buildup of fluid known as ascites. Current treatments using a combination of chemotherapy and immune therapy, like nivolumab, have shown improvements in survival rates. However, patients with specific conditions such as peritoneal metastasis and significant ascites have not had as good outcomes. This study aims to explore whether adding lenvatinib, a drug that targets tumor growth by blocking certain pathways, can enhance the effectiveness of the existing treatment combination. Participants in this trial will receive lenvatinib along with nivolumab and chemotherapy. The study seeks to determine if this combination can improve survival outcomes for patients who have been difficult to treat with current methods. The treatment will be administered through injections and pills, and researchers will monitor the participants closely to evaluate the drug's effectiveness and safety. The hope is that this combination could offer a new, more effective treatment for those facing this challenging condition and improve their quality of life.